Adedokun, A.; Adigun, O.; Muhammad, A.; Idris, I.; Ntasin, P.; Olowu, B.; Ikele-Awaogu, C.; Fadele, P.; Dibia, E. Exploring Immunotherapeutic Strategies For Bacterial And Viral Diseases: Recent Advances, Challenges And Future Perspectives. Preprints2024, 2024110105. https://doi.org/10.20944/preprints202411.0105.v1
APA Style
Adedokun, A., Adigun, O., Muhammad, A., Idris, I., Ntasin, P., Olowu, B., Ikele-Awaogu, C., Fadele, P., & Dibia, E. (2024). Exploring Immunotherapeutic Strategies For Bacterial And Viral Diseases: Recent Advances, Challenges And Future Perspectives. Preprints. https://doi.org/10.20944/preprints202411.0105.v1
Chicago/Turabian Style
Adedokun, A., Precious Fadele and Ernesto Dibia. 2024 "Exploring Immunotherapeutic Strategies For Bacterial And Viral Diseases: Recent Advances, Challenges And Future Perspectives" Preprints. https://doi.org/10.20944/preprints202411.0105.v1
Abstract
Antimicrobial resistance (AMR) is a growing global threat, affecting the effectiveness of antimicrobials and posing significant challenges in the treatment of bacterial and viral infections. The emergence of the coronavirus in 2019 and the ongoing menace of infectious diseases such as HIV/AIDS, tuberculosis, and hepatitis remind us of the impact infections have on economic stability and global health, and therefore, the need for a more holistic and long-term solution as opposed to antibiotics - measures that were previously relied on. This review explores recent advances in immunotherapeutic strategies, particularly cytokine-based therapies, adoptive cell therapy, monoclonal antibodies, and immune checkpoint inhibitors, in the control of AMR. It focuses on pathogens with high clinical relevance, including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Mycobacterium tuberculosis, and viral threats such as HIV and SARS-CoV-2. New inventive approaches such as CAR T cell therapy and MAIT cells were discussed in the context of bacterial and viral infections, highlighting promising results from clinical trials and addressing the challenges of toxicity, immune evasion, and therapy resistance inherent in these diseases. Future priorities include optimizing combination therapies and exploring new immunomodulatory targets to improve these interventions' effectiveness in treating AMR and other infectious diseases.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
